Zydus Lifesciences Ltd Valuation Shifts: From Attractive to Fair Amid Sector Dynamics

Valuation Metrics and Recent Changes

As of early May 2026, Zydus Lifesciences trades at ₹939.10, up 2.99% from the previous close of ₹911.85. The stock’s 52-week range spans from ₹835.85 to ₹1,059.00, indicating a moderate recovery from its lows but still below its peak levels. The company’s P/E ratio currently stands at 18.23, a figure that has contributed to the downgrade in its valuation grade from attractive to fair. This P/E is notably lower than some of its more expensive peers but higher than those deemed very attractive or attractive within the sector.

The price-to-book value ratio has also shifted, now at 3.74, reflecting a more tempered market valuation of the company’s net assets. Other valuation multiples such as EV to EBIT (14.06), EV to EBITDA (12.07), and EV to sales (3.72) further corroborate this moderate stance. The PEG ratio of 1.26 suggests that while earnings growth is factored into the valuation, it is not at a level that would justify a premium rating.

Comparative Analysis with Sector Peers

When compared with key competitors in the Pharmaceuticals & Biotechnology sector, Zydus Lifesciences’ valuation appears balanced but less compelling. Lupin, for instance, is rated as very attractive with a higher P/E of 22.44 but a significantly lower PEG ratio of 0.31, indicating better growth prospects relative to price. Similarly, Glenmark Pharma is also considered very attractive with a P/E of 27.52 and a PEG of 0.03, signalling strong growth expectations.

Conversely, companies such as Laurus Labs and Anthem Biosciences are classified as very expensive, with P/E ratios of 71.52 and 85.98 respectively, far exceeding Zydus Lifesciences’ valuation. This spectrum of valuations within the sector highlights that while Zydus is no longer at the top of the attractiveness scale, it remains reasonably valued compared to the most expensive peers.

Other notable peers include Aurobindo Pharma and Alkem Laboratories, which are rated fair and attractive respectively, with P/E ratios of 24.4 and 27.53. This places Zydus Lifesciences slightly below these companies in terms of valuation multiples, reinforcing the rationale behind the recent downgrade in its mojo grade from Hold to Sell.

Financial Performance and Quality Metrics

Zydus Lifesciences continues to demonstrate robust operational efficiency, with a return on capital employed (ROCE) of 23.72% and a return on equity (ROE) of 20.19%. These figures underscore the company’s ability to generate healthy returns on invested capital and shareholder equity, which partially offsets concerns arising from valuation moderation.

The dividend yield stands at 1.17%, a modest but stable return for investors seeking income alongside capital appreciation. The company’s EV to capital employed ratio of 3.49 further indicates a reasonable valuation relative to the capital base, supporting the fair valuation grade.

Stock Performance Relative to Market Benchmarks

Examining Zydus Lifesciences’ stock returns relative to the Sensex reveals a mixed but generally favourable trend. Over the past week, the stock has outperformed the Sensex with a 3.15% gain versus the benchmark’s 0.60%. The one-month return of 8.40% also surpasses the Sensex’s 5.20%, reflecting short-term momentum.

Year-to-date, Zydus has delivered a positive 2.67% return while the Sensex has declined by 8.52%, highlighting relative resilience amid broader market weakness. Over longer horizons, the stock’s 3-year return of 81.86% significantly outpaces the Sensex’s 27.69%, although the 5-year and 10-year returns of 56.05% and 195.18% respectively slightly trail the benchmark’s 59.26% and 209.01% gains.

This performance profile suggests that while Zydus Lifesciences has been a strong performer in recent years, its valuation adjustment may reflect a recalibration of growth expectations and market positioning.

Mojo Score and Grade Implications

MarketsMOJO’s latest assessment assigns Zydus Lifesciences a mojo score of 45.0, accompanied by a mojo grade of Sell, downgraded from Hold as of 1 December 2025. This downgrade aligns with the shift in valuation grade from attractive to fair, signalling caution for investors considering fresh exposure at current price levels.

The mid-cap classification of Zydus Lifesciences places it in a competitive segment where valuation discipline and growth visibility are critical. The downgrade reflects a more conservative stance on the stock’s risk-reward profile amid evolving sector dynamics and peer valuations.

Outlook and Investor Considerations

Investors analysing Zydus Lifesciences must weigh the company’s solid operational metrics and relative stock performance against the tempered valuation outlook. The shift from attractive to fair valuation suggests that the market is pricing in a more cautious growth trajectory or increased competitive pressures within the Pharmaceuticals & Biotechnology sector.

While the company’s P/E ratio of 18.23 remains reasonable compared to the broader market and some peers, it no longer offers the compelling discount that previously attracted investors. The moderate dividend yield and strong returns on capital provide some cushion, but the mojo grade downgrade to Sell indicates that better risk-adjusted opportunities may exist elsewhere.

Given the sector’s diversity in valuation—from very attractive to very expensive stocks—investors should consider peer comparisons carefully. Companies like Lupin and Glenmark Pharma, with their very attractive ratings and lower PEG ratios, may offer superior growth potential relative to price. Conversely, the very expensive valuations of Laurus Labs and Anthem Biosciences highlight the spectrum of risk and reward within the sector.

In summary, Zydus Lifesciences Ltd’s valuation adjustment reflects a market recalibration amid evolving fundamentals and competitive dynamics. Investors should monitor upcoming earnings releases and sector developments closely to reassess the company’s investment merit in the context of shifting market conditions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today